Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon.
Identifieur interne : 003635 ( PubMed/Checkpoint ); précédent : 003634; suivant : 003636Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon.
Auteurs : Tomoyuki Uchiyama [Japon] ; Ryuji Sakakibara ; Takamichi Hattori ; Tomonori YamanishiSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2003.
English descriptors
- KwdEn :
- Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Female, Humans, Levodopa (pharmacology), Levodopa (therapeutic use), Male, Middle Aged, Muscle, Smooth (drug effects), Parkinson Disease (complications), Parkinson Disease (drug therapy), Severity of Illness Index, Time Factors, Urethra (drug effects), Urethra (physiopathology), Urinary Bladder (drug effects), Urinary Incontinence (diagnosis), Urinary Incontinence (epidemiology), Urinary Incontinence (etiology), Urination Disorders (diagnosis), Urination Disorders (etiology), Urodynamics (drug effects).
- MESH :
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- complications : Parkinson Disease.
- diagnosis : Urinary Incontinence, Urination Disorders.
- drug effects : Muscle, Smooth, Urethra, Urinary Bladder, Urodynamics.
- drug therapy : Parkinson Disease.
- epidemiology : Urinary Incontinence.
- etiology : Urinary Incontinence, Urination Disorders.
- physiopathology : Urethra.
- Female, Humans, Male, Middle Aged, Severity of Illness Index, Time Factors.
Abstract
We investigated the short-term effects of a single dose of levodopa (L-dopa) on micturition function in PD patients with wearing-off phenomenon. Eighteen PD patients who had median Hoehn and Yahr scores of 5 during the off phase and 3 during the on phase were recruited. We carried out urodynamic studies before and about 1 hour after the patients had taken 100 mg of L-dopa with dopa-decarboxylase inhibitor (DCI). After taking the L-dopa/DCI, urinary urgency and urge incontinence aggravated, whereas voiding difficulty was alleviated in all 12 patients. When compared to the baseline assessment, urodynamic study results after taking 100 mg of L-dopa/DCI showed aggravated detrusor hyperreflexia; decreased maximum bladder capacity (P = 0.006); an increased maximum Watts Factor value (P = 0.001), reflecting the detrusor power on voiding; an increased Abrams-Griffiths number (P = 0.042), reflecting urethral obstruction on voiding; decreased residual urine volume (P = 0.025); and increased static urethral closure pressure (P = 0.012). One hundred milligrams of L-dopa/DCI worsened detrusor hyperreflexia, producing worsened urinary urgency and urge incontinence during the storage (bladder-filling) phase. It also increased detrusor contractility much more than it did urethral obstruction in the voiding phase, producing overall lessening of voiding difficulty and improving voiding efficiency in our PD patients with the wearing-off phenomenon.
DOI: 10.1002/mds.10403
PubMed: 12722172
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:12722172Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon.</title><author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan. uchito@js5.so-net.ne.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Graduate School of Medicine, Chiba University, Chiba</wicri:regionArea><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name></author><author><name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name></author><author><name sortKey="Yamanishi, Tomonori" sort="Yamanishi, Tomonori" uniqKey="Yamanishi T" first="Tomonori" last="Yamanishi">Tomonori Yamanishi</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12722172</idno><idno type="pmid">12722172</idno><idno type="doi">10.1002/mds.10403</idno><idno type="wicri:Area/PubMed/Corpus">003788</idno><idno type="wicri:Area/PubMed/Curation">003788</idno><idno type="wicri:Area/PubMed/Checkpoint">003635</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon.</title><author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan. uchito@js5.so-net.ne.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Graduate School of Medicine, Chiba University, Chiba</wicri:regionArea><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name></author><author><name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name></author><author><name sortKey="Yamanishi, Tomonori" sort="Yamanishi, Tomonori" uniqKey="Yamanishi T" first="Tomonori" last="Yamanishi">Tomonori Yamanishi</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (pharmacology)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Female</term><term>Humans</term><term>Levodopa (pharmacology)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Muscle, Smooth (drug effects)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Urethra (drug effects)</term><term>Urethra (physiopathology)</term><term>Urinary Bladder (drug effects)</term><term>Urinary Incontinence (diagnosis)</term><term>Urinary Incontinence (epidemiology)</term><term>Urinary Incontinence (etiology)</term><term>Urination Disorders (diagnosis)</term><term>Urination Disorders (etiology)</term><term>Urodynamics (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Urinary Incontinence</term><term>Urination Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Muscle, Smooth</term><term>Urethra</term><term>Urinary Bladder</term><term>Urodynamics</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Urinary Incontinence</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Urinary Incontinence</term><term>Urination Disorders</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Urethra</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We investigated the short-term effects of a single dose of levodopa (L-dopa) on micturition function in PD patients with wearing-off phenomenon. Eighteen PD patients who had median Hoehn and Yahr scores of 5 during the off phase and 3 during the on phase were recruited. We carried out urodynamic studies before and about 1 hour after the patients had taken 100 mg of L-dopa with dopa-decarboxylase inhibitor (DCI). After taking the L-dopa/DCI, urinary urgency and urge incontinence aggravated, whereas voiding difficulty was alleviated in all 12 patients. When compared to the baseline assessment, urodynamic study results after taking 100 mg of L-dopa/DCI showed aggravated detrusor hyperreflexia; decreased maximum bladder capacity (P = 0.006); an increased maximum Watts Factor value (P = 0.001), reflecting the detrusor power on voiding; an increased Abrams-Griffiths number (P = 0.042), reflecting urethral obstruction on voiding; decreased residual urine volume (P = 0.025); and increased static urethral closure pressure (P = 0.012). One hundred milligrams of L-dopa/DCI worsened detrusor hyperreflexia, producing worsened urinary urgency and urge incontinence during the storage (bladder-filling) phase. It also increased detrusor contractility much more than it did urethral obstruction in the voiding phase, producing overall lessening of voiding difficulty and improving voiding efficiency in our PD patients with the wearing-off phenomenon.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12722172</PMID><DateCreated><Year>2003</Year><Month>04</Month><Day>30</Day></DateCreated><DateCompleted><Year>2003</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>5</Issue><PubDate><Year>2003</Year><Month>May</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon.</ArticleTitle><Pagination><MedlinePgn>573-8</MedlinePgn></Pagination><Abstract><AbstractText>We investigated the short-term effects of a single dose of levodopa (L-dopa) on micturition function in PD patients with wearing-off phenomenon. Eighteen PD patients who had median Hoehn and Yahr scores of 5 during the off phase and 3 during the on phase were recruited. We carried out urodynamic studies before and about 1 hour after the patients had taken 100 mg of L-dopa with dopa-decarboxylase inhibitor (DCI). After taking the L-dopa/DCI, urinary urgency and urge incontinence aggravated, whereas voiding difficulty was alleviated in all 12 patients. When compared to the baseline assessment, urodynamic study results after taking 100 mg of L-dopa/DCI showed aggravated detrusor hyperreflexia; decreased maximum bladder capacity (P = 0.006); an increased maximum Watts Factor value (P = 0.001), reflecting the detrusor power on voiding; an increased Abrams-Griffiths number (P = 0.042), reflecting urethral obstruction on voiding; decreased residual urine volume (P = 0.025); and increased static urethral closure pressure (P = 0.012). One hundred milligrams of L-dopa/DCI worsened detrusor hyperreflexia, producing worsened urinary urgency and urge incontinence during the storage (bladder-filling) phase. It also increased detrusor contractility much more than it did urethral obstruction in the voiding phase, producing overall lessening of voiding difficulty and improving voiding efficiency in our PD patients with the wearing-off phenomenon.</AbstractText><CopyrightInformation>Copyright 2003 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uchiyama</LastName><ForeName>Tomoyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan. uchito@js5.so-net.ne.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakakibara</LastName><ForeName>Ryuji</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hattori</LastName><ForeName>Takamichi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yamanishi</LastName><ForeName>Tomonori</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009130">Muscle, Smooth</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014521">Urethra</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001743">Urinary Bladder</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014549">Urinary Incontinence</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014555">Urination Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014563">Urodynamics</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>5</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>5</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12722172</ArticleId><ArticleId IdType="doi">10.1002/mds.10403</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Japon</li></country></list><tree><noCountry><name sortKey="Hattori, Takamichi" sort="Hattori, Takamichi" uniqKey="Hattori T" first="Takamichi" last="Hattori">Takamichi Hattori</name><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name><name sortKey="Yamanishi, Tomonori" sort="Yamanishi, Tomonori" uniqKey="Yamanishi T" first="Tomonori" last="Yamanishi">Tomonori Yamanishi</name></noCountry><country name="Japon"><noRegion><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003635 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003635 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:12722172
|texte= Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:12722172" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |